What is Global Plasma for Fractionation Market?
The Global Plasma for Fractionation Market is a significant sector in the healthcare industry that focuses on the use of blood plasma for various medical treatments. Blood plasma, the liquid component of blood, is rich in proteins and is used in the production of therapies for a range of life-threatening conditions. The process of fractionation involves separating these proteins from the plasma to create different therapeutic products. The global market for plasma fractionation was valued at US$ 28780 million in 2022 and is projected to reach US$ 32600 million by 2029. This indicates a Compound Annual Growth Rate (CAGR) of 2.1% during the forecast period from 2023 to 2029.
Recovered Plasma, Source Plasma in the Global Plasma for Fractionation Market:
The Global Plasma for Fractionation Market is divided into two main categories: Recovered Plasma and Source Plasma. Recovered Plasma is obtained from whole blood donations, while Source Plasma is collected through a process called plasmapheresis, where the plasma is separated from the blood cells and the cells are returned to the donor. Both types of plasma are crucial for the production of life-saving therapies. However, the specific use of each type depends on the requirements of the therapeutic product being manufactured. For instance, some therapies require specific proteins that are more abundant in one type of plasma than the other.
Coagulation Factor, Immune Globulin, Albumin, Others in the Global Plasma for Fractionation Market:
The Global Plasma for Fractionation Market plays a vital role in the production of various therapeutic products. These include Coagulation Factor, Immune Globulin, Albumin, and others. Coagulation Factor is used in the treatment of bleeding disorders such as hemophilia. Immune Globulin is used to boost the immune system in patients with immune deficiencies. Albumin is used to treat a variety of conditions including shock, burns, and liver disease. Other products derived from plasma include hyperimmune globulins and antithrombin III concentrates. Each of these products plays a crucial role in treating a range of serious health conditions, highlighting the importance of the plasma fractionation market.
Global Plasma for Fractionation Market Outlook:
To rephrase the market outlook, the Global Plasma for Fractionation Market, which was valued at US$ 28780 million in 2022, is expected to grow to US$ 32600 million by 2029. This represents a CAGR of 2.1% during the forecast period of 2023 to 2029. In terms of product segmentation, Immune Globulin holds the largest share, accounting for about 51% of the market. This indicates the significant role of Immune Globulin in the plasma fractionation market and its widespread use in the healthcare industry.
| Report Metric | Details |
| Report Name | Plasma for Fractionation Market |
| Accounted market size in 2022 | US$ 9541 million |
| Forecasted market size in 2029 | US$ 15840 million |
| CAGR | 7.6% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, Hualan Bio |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
